Medical management of ulcerative colitis
Medical management of IBD varies with respect to disease severity:
Considered in terms of:
- acute attacks
- maintenance of remission of IBD
Related pages
- Maintenance therapy in UC
- Management of acute ulcerative colitis
- Chronic ulcerative colitis
- Leukapharesis for inflammatory bowel disease
- Clinical based scales to assess severity of ulcerative colitis (UC)
- Infliximab in Crohn's disease and ulcerative (UC) colitis
- NICE guidance - Tofacitinib for moderately to severely active ulcerative colitis
- NICE guidance - Vedolizumab for treating moderately to severely active ulcerative colitis
- NICE guidance - Ustekinumab for treating moderately to severely active ulcerative colitis
- Faecal microbiota transplantation (FMT) in ulcerative colitis (UC)
- Filgotinib for treating moderately to severely active ulcerative colitis
- Ozanimod for treating moderately to severely active ulcerative colitis
- Upadacitinib for treating moderately to severely active ulcerative colitis (UC)
- Mirikizumab for treating moderately to severely active ulcerative colitis (UC)
- Exercise and inflammatory bowel disease (IBD)
- Risankizumab for treating moderately to severely active ulcerative colitis
Create an account to add page annotations
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page